[Ip-health] GARDP on WHO antibiotic pipeline report

Rachel Cohen rachel.cohen72 at gmail.com
Tue Sep 19 15:09:38 PDT 2017

*The world is running out of antibiotics, WHO report confirms*

A report – “Antibacterial agents in clinical development – an analysis of
the antibacterial clinical development pipeline, including Mycobacterium
tuberculosis” – launched today by the World Health Organization (WHO) shows
a serious lack of new antibiotics under development to combat the growing
threat of antimicrobial resistance.

“This report provides firm evidence which confirms that the clinical
pipeline for new antibiotics is extremely weak. This is a major wake-up
call for greater investments into research and development for new
antibiotics. Support also needs to be targeted towards early-stage
research, so that we can start to identify new candidate drugs for
development. It is also critical that the biggest and most urgent public
health needs receive the greatest attention, first and foremost.

The Global Antibiotic Research and Development Partnership (GARDP) was set
up by the World Health Organization (WHO) and the Drugs for Neglected
Diseases *initiative* (DND*i*) to develop new or improved antibiotics to
develop new treatments for key WHO pathogens and important public health
threats such as neonatal sepsis and sexually transmitted infections. In
July of this year, GARDP announced a partnership with Entasis Therapeutics
to develop a new treatment to address the rapidly-growing threat of
drug-resistant gonorrhoea.”

Dr Manica Balasegaram, GARDP Director

Rachel M. Cohen
Regional Executive Director
Drugs for Neglected Diseases initiative (DNDi), North America
40 Wall Street, 24th Floor, New York, NY 10005
Mob: +1.646.824.3064
Office: +1.646.616.8683
Email: rcohen at dndi.org
Web: www.dndi.org
Best Science for the Most Neglected

More information about the Ip-health mailing list